Monopar Therapeutics Inc

Research Monopar Therapeutics Inc (MNPR) on Bullrun: market cap USD 633.47M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMNPR
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 633.47M
• Financial periodFY2025
• Net income-USD 13.72M

Valuation Snapshot

latest market cap is USD 633.47M.

About Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor;

Frequently asked questions

What is Monopar Therapeutics Inc's market cap?

Monopar Therapeutics Inc's market capitalization is USD 633.47M.

What does Monopar Therapeutics Inc do?

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine;